Abstract
The androgen receptor (AR) plays a pivotal role in the progression of prostate cancer from the androgen-dependent to the castration-resistant state, making it a potential target for therapy. In this chapter, we describe the preparation and use of sublines of LNCaP and C4-2 human prostate cancer cells which have been engineered to stably express a doxycycline (DOX)-inducible AR shRNA in order to study the in vitro and in vivo effects of AR knockdown.
Author supplied keywords
Cite
CITATION STYLE
Cheng, H., Leblanc, E., & Rennie, P. S. (2011). In Vitro and In Vivo Silencing of the Androgen Receptor. In Methods in Molecular Biology (Vol. 776, pp. 95–112). Humana Press Inc. https://doi.org/10.1007/978-1-61779-243-4_7
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
